Nothing Special   »   [go: up one dir, main page]

DE602004016547D1 - 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen - Google Patents

1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Info

Publication number
DE602004016547D1
DE602004016547D1 DE602004016547T DE602004016547T DE602004016547D1 DE 602004016547 D1 DE602004016547 D1 DE 602004016547D1 DE 602004016547 T DE602004016547 T DE 602004016547T DE 602004016547 T DE602004016547 T DE 602004016547T DE 602004016547 D1 DE602004016547 D1 DE 602004016547D1
Authority
DE
Germany
Prior art keywords
compounds
myhc
dihydropyridine
treatment
cardiac disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004016547T
Other languages
English (en)
Inventor
Kathy Schreiber
Larry Melvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Colorado Inc
Original Assignee
Myogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myogen Inc filed Critical Myogen Inc
Publication of DE602004016547D1 publication Critical patent/DE602004016547D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004016547T 2003-11-03 2004-11-03 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen Expired - Lifetime DE602004016547D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51682803P 2003-11-03 2003-11-03
PCT/US2004/036568 WO2005042486A1 (en) 2003-11-03 2004-11-03 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
DE602004016547D1 true DE602004016547D1 (de) 2008-10-23

Family

ID=34549573

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016547T Expired - Lifetime DE602004016547D1 (de) 2003-11-03 2004-11-03 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Country Status (9)

Country Link
US (1) US7485653B2 (de)
EP (1) EP1685107B1 (de)
JP (1) JP2007510727A (de)
AT (1) ATE407925T1 (de)
AU (1) AU2004285961A1 (de)
CA (1) CA2544763A1 (de)
DE (1) DE602004016547D1 (de)
IL (1) IL175358A0 (de)
WO (1) WO2005042486A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015246A2 (en) * 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
WO2007076379A2 (en) * 2005-12-20 2007-07-05 Gilead Colorado, Inc. 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
KR101378067B1 (ko) 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
EP2544676B1 (de) 2010-03-10 2018-09-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Verwendung von fenoterol und fenoterolanalogen bei der behandlung von glioblastomen und astrozytomen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920225A (en) * 1986-12-22 1990-04-24 Laboratoires Syntex S.A. Resolution of 1,4-dihydropyridine derivatives
TW215434B (de) * 1992-03-07 1993-11-01 Hoechst Ag
CA2277965A1 (en) 1997-02-04 1998-08-06 Marc A. Bruce Dihydropyrimidone derivatives as npy antagonists
EP1470108B1 (de) * 2002-01-18 2016-08-24 Vittal Mallya Scientific Research Foundation 1,4-dihydropyridin- und pyridinderivate als calcium-kanal-blocker
CA2483311A1 (en) * 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto

Also Published As

Publication number Publication date
US20050124633A1 (en) 2005-06-09
WO2005042486A1 (en) 2005-05-12
AU2004285961A1 (en) 2005-05-12
EP1685107A1 (de) 2006-08-02
CA2544763A1 (en) 2005-05-12
IL175358A0 (en) 2006-09-05
ATE407925T1 (de) 2008-09-15
EP1685107B1 (de) 2008-09-10
US7485653B2 (en) 2009-02-03
JP2007510727A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
CY1118179T1 (el) Φαρμακευτικη συνθεση
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005107726A3 (en) Method for the treatment of back pain
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DE602004002585D1 (de) VERWENDUNG EINER PHARMAZEUTISCHEN FORMULIERUNG ENTHALTEND MILCHSÄURE ODER LAKTAT UND kALIUM ZUR BEHANDLUNG VON HIRNÖDEM UND VERLETZUNGEN DES GEHIRNS
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60335892D1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition